929891-72-5Relevant academic research and scientific papers
five Yuan fragrance heterocyclic structure containing the anti-hepatitis c compound and its preparation and use
-
, (2016/11/21)
The invention discloses an anti-HCV (hepatitis C) compound containing a five-membered heteroaromatic ring structure, as well as a preparation method and applications thereof. The compound has a structure shown as the formula I, the compound has excellent anti-HCV virus activity, can be used for preparing anti-HCV drugs, the prepared drugs can be applied by adopting oral administration, intravenous injection or intramuscular injection.
A Survey of the Borrowing Hydrogen Approach to the Synthesis of some Pharmaceutically Relevant Intermediates
Leonard, John,Blacker, A. John,Marsden, Stephen P.,Jones, Martin F.,Mulholland, Keith R.,Newton, Rebecca
, p. 1400 - 1410 (2015/11/02)
The use of the "borrowing hydrogen strategy" in the synthesis of a number of typical pharmaceutical intermediates has been investigated. The main aim of this work was to investigate the scope and limitations of current methodology using standard laboratory techniques in an industrial context. Some interesting and significant results were achieved across a diverse set of complex substrates; however several drawbacks with this approach were identified, such as the high loading, poor turnover, and susceptibility to substrate inactivation of the catalysts. These are areas which are highlighted for future investigation and improvements.
NOVEL COMPOUNDS - 644
-
, (2010/09/05)
The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6 and L are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of hepatitis C virus.
HETEROCYCLIC DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C
-
, (2009/04/25)
Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or alleviating HCV, formula (I): wherein R1, R2, R4, Y1, Y2, Y3, A, B and W are as defined in the specification.
